PARIS - The share price of NicOx SA on the Nouveau Marché in Paris plummeted by more than 83 percent last week after AstraZeneca plc issued a statement in the names of both companies announcing that the recently completed Phase II trial of a drug candidate they are developing did not attain its primary therapeutic objective. (BioWorld International) Read More
